| Document |
Document Title |
|
WO/2022/233302A1 |
The present invention provides a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically-a...
|
|
WO/2022/235557A1 |
Methods of treating a metabolic disorder in a subject are provided. Aspects of the method include administering an effective amount of an N-lactoyl-amino acid to the subject. Also provided are pharmaceutical formulations including an amo...
|
|
WO/2022/233767A1 |
Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs), wherein the stem cell function is increased for at least 40 weeks.
|
|
WO/2022/233398A1 |
The present invention relates to a polyhydroxylated bile acid compound or a pharmaceutically acceptable salt thereof for use in the treatment of a subject suffering from an increased plasma level of lipoprotein (a) (Lp(a)).
|
|
WO/2022/234963A1 |
The present invention relates to a peptide, of a novel sequence, characterized by being gelled in accordance with the pH condition. Since the peptide may induce blood coagulation, a composition comprising the peptide can be utilized for ...
|
|
WO/2022/230487A1 |
The purpose of the present invention is to provide: a composition for increasing red blood cells and/or hemoglobin; a composition for preventing or ameliorating anemia; a composition for improving endurance; an anti-fatigue composition; ...
|
|
WO/2022/230793A1 |
The purpose of the present invention is to provide a compound that promotes the maintenance and multiplication of hematopoietic stem cells, and is useful in the cultivation and similar of hematopoietic stem cells that can be used in hema...
|
|
WO/2022/232460A1 |
Provided herein are safe and effective dosing regimens for mitapivat and/or pharmaceutically acceptable salts thereof.
|
|
WO/2022/231627A1 |
Provided herein are safe and effective dosing regimens for mitapivat and pharmaceutically acceptable salts thereof.
|
|
WO/2022/231999A1 |
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression ...
|
|
WO/2022/232435A1 |
Provided herein, in part, are methods of downregulating BCL11A expression and treatment of BCL11A mediated disorders. The methods may comprise the use of inhibitors such as EED, EHZ2, and/or PRC2 inhibitors.
|
|
WO/2022/228087A1 |
Provided are recombinant coagulation factor VIII and application use thereof. The recombinant coagulation factor VIII includes more than 80% of an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. Through gene modification of...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/228551A1 |
The present disclosure relates to an administration scheme for a thrombopoietin receptor agonist. Specifically, provided in the present disclosure is a method for treating thrombocytopenia, comprising administering to a patient a therape...
|
|
WO/2022/229150A1 |
The invention relates to a Matriptase-2 (MT2) and/or TMPRSS6 inhibitor for the prevention, decrease of the risk of suffering from or treatment of a myeloproliferative disorder.
|
|
WO/2022/223689A1 |
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicam...
|
|
WO/2022/226013A1 |
This application provides a highly safe pharmaceutical composition containing SMTP-7 or a salt, ester or solvate thereof as an active ingredient, wherein the said pharmaceutical composition further containing either or both of a basic ad...
|
|
WO/2022/224249A1 |
There is provided procoagulant peptides, and use of same, such as in treatment of hemostasis-related diseases or disorders, and/or wound healing.
|
|
WO/2021/256470A9 |
The present invention is to provide a composition for inducing, enhancing and/or balancing an immune response, comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327). The present invention is also to provi...
|
|
WO/2022/225045A1 |
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The present invention provides a therapeutic or prophylactic agent for cachexia accompanied by g...
|
|
WO/2022/222960A1 |
Disclosed are a substituted pyridone macrocyclic compound represented by formula I, a pharmaceutical composition and the use thereof. The compound has an FXIa inhibitory effect, good pharmacokinetics and other properties, and can be used...
|
|
WO/2022/226048A1 |
Methods for immune tolerance induction and eradication of anti-drug antibodies to therapeutic Factor VIII are disclosed.
|
|
WO/2022/226294A1 |
The invention relates to chimeric AAV5 capsids, virus vectors comprising the same, and methods of using the vectors such as to target the liver. The invention further relates to chimeric AAV5 capsids with improved infectivity to hepatocy...
|
|
WO/2022/225828A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit f...
|
|
WO/2022/225420A1 |
The invention relates to the field of pharmaceutics, and more particularly to a pharmacological composition for treating iron deficiency anaemia, containing iron (II) sulphate and characterized in that it further contains iron-potassium-...
|
|
WO/2022/221527A1 |
Methods for treating and/or preventing drug-induced thrombocytopenia (DITP) and vaccine-induced thrombosis and thrombocytopenia syndrome (VITT) with certain BTK inhibitors and/or pharmaceutically acceptable salts thereof are provided.
|
|
WO/2022/218163A1 |
Provided are an RNA inhibitor for inhibiting hepatitis B virus (HBV) gene expression and an application thereof. The RNA inhibitor is formed of a sense strand and an antisense strand by means of base pairing; at least 85% of bases of the...
|
|
WO/2022/221441A2 |
Products, compositions, and their uses are provided. In particular, nucleic acid products that modulate, in particular interfere with or inhibit, Factor XI (FXI) gene expression are provided. The products can be oligomeric compounds that...
|
|
WO/2022/215704A1 |
The present invention pertains to a conjugate body represented by Lg-Lk-NCA wherein Lk is a linker moiety, NCA is a nucleic acid moiety and Lg is a group represented by one of the formulae.
|
|
WO/2022/217105A1 |
An ionic, electrically activated, aqueous or dry mixture includes dissolved minerals, undissolved minerals, and inert, structured, mineral microparticles. The aqueous or dry mixture may be formulated to make the active ingredients system...
|
|
WO/2022/213212A1 |
DPEP-1 binding agents, including antibodies, and pharmaceutical compositions containing the same are described. Also provided are methods for using and manufacturing such binding agents, antibodies and pharmaceutical compositions, as wel...
|
|
WO/2022/213896A1 |
The present invention provides a quinoxaline compound, a preparation method, and a pharmaceutical application thereof, and particularly relates to a quinoxaline compound having PAR4 antagonistic activity and a preparation method therefor...
|
|
WO/2022/211604A1 |
The present invention relates to stem cells edited with a FE-FVIII mutant gene, endothelial cells differentiated therefrom, and a pharmaceutical composition containing same for prevention or treatment of hemophilia. The composition, the ...
|
|
WO/2022/211791A1 |
Modified hum 1. an factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, F57, L69,...
|
|
WO/2022/212813A1 |
Disclosed herein, in part, are methods of subcutaneously administering liquid pharmaceutical formulations containing furosemide to a patient using a shortened infusion profile. Methods of treating condition such as congestion due to flui...
|
|
WO/2022/206090A1 |
A pentoxifylline injection. A preparation method for the pentoxifylline injection comprises: adding an osmotic pressure regulator of a prescribed amount into injection water that accounts for 40-60% of a total preparation volume and stir...
|
|
WO/2022/207924A1 |
The present invention relates to compounds of formula (I). The compounds of the formula (I) are e.g. (S)-1-(5-((pyridin-3-yl)thio) pyrazin-2-yl)-4lH,6'H-spiro[piperidine-4,5'-pyrrolo[l,2-b]py
razol]-4l- amine derivatives and similar comp...
|
|
WO/2022/206986A1 |
Provided are gene therapy technologies, including specifically designed and tested guide RNA sequences for improved base editors, useful for increasing the expression of the gamma-globin gene. The guide RNA sequences may target the BCL11...
|
|
WO/2022/212645A1 |
Provided herein are methods for reducing or preventing surgery-associated hemolysis in subjects who have cold agglutinin disease (CAD) (e.g., been diagnosed with CAD or have had at least one symptom of CAD).
|
|
WO/2022/199552A1 |
Disclosed are an alpha-globin overexpression vector and an application thereof. The alpha-globin overexpression vector sequentially comprises: (1) a locus control region, an alpha-globin promoter, an HBA2 gene and a HBA2 gene 3'sequence ...
|
|
WO/2022/198361A1 |
Disclosed is a novel crystal form of dabigatran etexilate ethyl ester hydrochloride, the X-ray powder diffraction pattern thereof having diffraction peaks at 2θ ± 0.2°, and 2θ is at least selected from any one of 5.42 ± 0.2°, 9.08 ...
|
|
WO/2022/200580A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The co...
|
|
WO/2022/196816A1 |
Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis. The pharmaceutica...
|
|
WO/2022/197761A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit f...
|
|
WO/2022/195532A1 |
Present invention relates to development of compound of formula (Ia) for treatment of sickle cell anaemia. Invention also relates to the pharmaceutical composition comprising compound of formula (Ia) or its pharmaceutically acceptable sa...
|
|
WO/2022/195355A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
|
WO/2022/195454A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
|
WO/2022/191330A1 |
Provided is a hemostatic material which can be safely used for more people, and is inexpensive and highly effective. Provided is a hemostatic material for preventing bleeding, which contains a cationized polysaccharide represented by for...
|
|
WO/2022/189279A1 |
The present invention relates to crystalline forms of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(t
rifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazo
la-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide which are...
|
|
WO/2022/192730A1 |
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing...
|
